Randomized Controlled Trial of Dexmedetomidine for the Treatment of Intensive Care Unit (ICU) Delirium

• Status: Completed
• Trial end date: 2012-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the research is to see if dexmedetomidine (a drug that has a calming effect - a sedative) is effective for the treatment of acute delirium

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Brigham and Women's Hospital
• Treatments: Dexmedetomidine

Criteria

Inclusion Criteria:

• Adults admitted to our surgical ICU who do not have any exclusion criteria

• Eligibility for treatment- Development of delirium as defined

Exclusion Criteria:

• Acute MI (myocardial infarction),

• Trauma <24 hours,

• Head injury,

• Multiple organ failure,

• EF (ejection fraction) < 30%,

• History of hypersensitivity to alpha2 agonist,

• History of seizures, MAP (mean arterial pressure) <60 mm of Hg,

• Dysrhythmias a/with bradycardia (HR (heart rate) <50),

• Need for vasopressors,

• Acute renal failure with a need for dialysis/CVVH (Continuous Veno-Venous Hemofiltration) or liver disease.

• Women of child bearing age who do not have a documented negative pregnancy test and/or who do not actively use contraception. (Documented negative pregnancy test will be a urine pregnancy test obtained on this admission)